HR+ Breast Cancer research hub

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

This study is testing a new drug, BLU-222, for people with certain advanced cancers, including breast, ovarian, and stomach cancers. It aims to see how safe the drug is, how it moves through the body, and if it helps shrink tumors, both on its own and with other treatments.